MX2016017405A - Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. - Google Patents
Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.Info
- Publication number
- MX2016017405A MX2016017405A MX2016017405A MX2016017405A MX2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A MX 2016017405 A MX2016017405 A MX 2016017405A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- atom
- halogen
- atoms
- hydrogen atom
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- -1 2-(3-pyridinyl)-1h-benzimidazole derivative compound Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006165 cyclic alkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002560 nitrile group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la fórmula general (I) o una sal del mismo, y a un medicamento que contiene una sal del compuesto (en la fórmula, R1 representa un átomo de hidrógeno o un radical CO2Ra; R2 representa un átomo de hidrógeno, un átomo de halógeno ó CO2Ra; R3 representa un átomo de hidrógeno o un radical hidroxialquilo de 1 a 10 átomos de carbono; R4 representa un átomo de hidrógeno, un radical hidroxi, o un radical alcoxi de 1 a 10 átomos de carbono; R5 representa un radical alquilo de cadena lineal de 1 a 5 átomos de carbono, en el cual los átomos de hidrógeno opcionalmente son sustituidos por átomos de halógeno, un radical alquilo cíclico de 3 a 5 átomos de carbono, en el cual los átomo de hidrógeno opcionalmente son sustituidos por átomos de halógeno, un radical hidroxialquilo de 1 a 5 átomos de carbono, o un radical o-, p- o m-halobencilo; A representa CH o un átomo de nitrógeno; X1 y X3 independientemente representan átomos de hidrógeno o átomos de halógeno; X2 representa un átomo de hidrógeno, un átomo de halógeno, o un radical nitrilo; por lo menos uno de entre X1, X2 y X3 representa un átomo de halógeno; y Ra independientemente representa un radical alquilo de 1 a 1' átomos de carbono).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014131934 | 2014-06-26 | ||
| PCT/JP2015/068431 WO2015199205A1 (ja) | 2014-06-26 | 2015-06-25 | ２－（３－ピリジニル）－１ｈ－ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017405A true MX2016017405A (es) | 2017-08-24 |
Family
ID=54938282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017405A MX2016017405A (es) | 2014-06-26 | 2015-06-25 | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10189815B2 (es) |
| EP (1) | EP3162802B1 (es) |
| JP (1) | JP6636921B2 (es) |
| KR (1) | KR20170017871A (es) |
| CN (1) | CN106458995B (es) |
| AU (1) | AU2015281060B2 (es) |
| CA (1) | CA2953692A1 (es) |
| ES (1) | ES2821273T3 (es) |
| MX (1) | MX2016017405A (es) |
| SG (1) | SG11201610217YA (es) |
| WO (1) | WO2015199205A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190255199A1 (en) * | 2016-06-10 | 2019-08-22 | Nihon Medi-Physics Co., Ltd. | Non-invasive diagnostic imaging agent for heart disease |
| US20200009273A1 (en) * | 2017-03-07 | 2020-01-09 | Nihon Medi-Physics Co., Ltd. | Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same |
| CN110809575A (zh) | 2017-06-23 | 2020-02-18 | 日本医事物理股份有限公司 | 放射性卤素标记化合物的制造方法及放射性医药的制造方法 |
| JP7054134B2 (ja) * | 2017-12-07 | 2022-04-13 | 国立大学法人京都大学 | ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング |
| JP7209970B2 (ja) * | 2017-12-28 | 2023-01-23 | 日本メジフィジックス株式会社 | ２－［５－（イミダゾール－１－イルメチル）ピリジン－３－イル］ベンズイミダゾール誘導体化合物、及び、これを含む医薬 |
| JP2021130610A (ja) * | 2018-05-08 | 2021-09-09 | 日本メジフィジックス株式会社 | 心疾患の非侵襲的画像診断剤 |
| JP2021181404A (ja) * | 2018-08-23 | 2021-11-25 | 日本メジフィジックス株式会社 | 放射性フッ素標識化合物の標識前駆体化合物を含有する溶液 |
| TW202016096A (zh) * | 2018-10-24 | 2020-05-01 | 日商日本醫事物理股份有限公司 | 放射性氟元素標示前驅物化合物的鹽類 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539822A (ja) * | 2006-06-09 | 2009-11-19 | ジーイー・ヘルスケア・リミテッド | 副腎のβ−１１−ヒドロキシラーゼの定量用トレーサーとしての１８Ｆ標識アルキル−１−［（１Ｒ）−１−フェニルエチル］−１Ｈ−イミダゾール−５−カルボキシレートの合成と評価 |
| EP2394668A1 (en) | 2010-06-01 | 2011-12-14 | Julius-Maximilians-Universität Würzburg | PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
| WO2012012478A1 (en) | 2010-07-21 | 2012-01-26 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
| JP2015110563A (ja) * | 2013-11-08 | 2015-06-18 | 日本メジフィジックス株式会社 | アルドステロン合成酵素阻害剤 |
-
2015
- 2015-06-25 JP JP2016529669A patent/JP6636921B2/ja active Active
- 2015-06-25 CN CN201580032760.3A patent/CN106458995B/zh active Active
- 2015-06-25 SG SG11201610217YA patent/SG11201610217YA/en unknown
- 2015-06-25 WO PCT/JP2015/068431 patent/WO2015199205A1/ja active Application Filing
- 2015-06-25 US US15/321,972 patent/US10189815B2/en active Active
- 2015-06-25 CA CA2953692A patent/CA2953692A1/en not_active Abandoned
- 2015-06-25 AU AU2015281060A patent/AU2015281060B2/en not_active Ceased
- 2015-06-25 ES ES15811977T patent/ES2821273T3/es active Active
- 2015-06-25 MX MX2016017405A patent/MX2016017405A/es unknown
- 2015-06-25 KR KR1020167028804A patent/KR20170017871A/ko not_active Withdrawn
- 2015-06-25 EP EP15811977.6A patent/EP3162802B1/en active Active
-
2018
- 2018-12-06 US US16/211,434 patent/US10358434B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201610217YA (en) | 2017-01-27 |
| EP3162802A1 (en) | 2017-05-03 |
| AU2015281060A1 (en) | 2017-01-05 |
| CN106458995B (zh) | 2019-12-20 |
| AU2015281060B2 (en) | 2019-03-14 |
| CA2953692A1 (en) | 2015-12-30 |
| CN106458995A (zh) | 2017-02-22 |
| US20170158668A1 (en) | 2017-06-08 |
| WO2015199205A1 (ja) | 2015-12-30 |
| JPWO2015199205A1 (ja) | 2017-04-20 |
| EP3162802B1 (en) | 2020-08-19 |
| JP6636921B2 (ja) | 2020-01-29 |
| US10358434B2 (en) | 2019-07-23 |
| ES2821273T3 (es) | 2021-04-23 |
| EP3162802A4 (en) | 2018-01-17 |
| US10189815B2 (en) | 2019-01-29 |
| US20190169169A1 (en) | 2019-06-06 |
| KR20170017871A (ko) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX2015010775A (es) | Benzoxazoles sustituidos y metodos para usarlos. | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| GEP20207111B (en) | Heteroaryl compounds for kinase inhibition | |
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| NZ732657A (en) | Picolinamides with fungicidal activity and other related compounds | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| NZ732810A (en) | Picolinamides and other compounds | |
| RS54730B1 (sr) | Inhibitori beta sekretaze | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX2015017156A (es) | Inhibidores de bace. | |
| CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
| PH12018501181A1 (en) | Phenyl derivatives as cannabinoid receptor 2 agonists | |
| PH12012501385A1 (en) | Piperazine compound having a pgds inhibitory effect | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| MX394157B (es) | Derivado de dihidropirrolopirazol sustituido. | |
| MX2016017371A (es) | Sal de compuesto heterociclico sustituido con halogeno. | |
| ZA202101487B (en) | Novel compounds | |
| MY185971A (en) | Pyranodipyridine compound | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MY193239A (en) | Novel b-lactamase inhibitors |